Anuradha Lala-Trindade, MD

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Anuradha Lala-Trindade, MD, shares developments in the pipeline for heart failure therapy, as well as clinical pearls for health care providers managing patients with heart failure.

Anuradha Lala-Trindade, MD, discusses the PARAGLIDE-HF trials, highlighting the use of sacubitril/valsartan for the management of heart failure in certain populations.

An expert cardiologist comments on unmet needs in the management of heart failure, highlighting the need to categorize patients with heart failure in order to better treat them.

Anuradha Lala-Trindade, MD, shares approaches to personalizing quadruple therapy for people with heart failure, focusing on family history, device-based therapies, and optimizing therapy early.

Anuradha Lala-Trindade, MD, provides an overview of SGLT2 inhibitors for the management of heart failure, as well as their clinical trial data.

An expert cardiologist reviews the foundational pillars of quadruple-based, guideline therapies for heart failure, as well as the contraindications for these drugs.

Anuradha Lala-Trindade, MD, comments on the prevalence of the various types of heart failure, as well as risk factors leading to the disorder.

Anuradha Lala-Trindade, MD, discusses the challenges in managing heart failure in the United States as well as the universal definition of heart failure and classification by left ventricle ejection fraction (EF).